Factors | MOG-IgG-positive group n = 35 | MOG-IgG-negative group n = 50 | B | p value | OR | 95% CI |
Gender, male, n (%) | 21 (60) | 28 (56) | 0.032 | 0.970 | 1.03 | (0.193, 5.509) |
Onset age, months, median (range) | 69 (20–138) | 76 (13–178) | −0.007 | 0.575 | 0.993 | (0.970, 1.017) |
Disease duration, days, median (range) | 10 (1–30)* | 6 (0.5–30) | 0.168 | 0.008 | 1.183 | (1.045, 1.339) |
Meningeal involvement, n (%) | 11 (31.4)* | 4 (8) | 4.445 | 0.001 | 85.158 | (6.199, 1169.853) |
Frontal lobe involvement, n (%) | 29 (82.9)* | 29 (58) | 2.703 | 0.027 | 51.824 | (2.867, 936.883) |
Relapse, n (%) | 5 (14.3) | 1 (2) | 2.978 | 0.106 | 19.639 | (0.533, 723.340) |
Serum TNF, (pg/ml), median (range) | 1.7 (1–12.4) | 2.2 (1–34) | −0.147 | 0.160 | 0.863 | (0.703, 1.060) |
Serum IFN-γ, (pg/ml), median (range) | 1.3 (1–9.4) | 3 (1–64) | −0.114 | 0.581 | 0.893 | (0.596, 1.336) |